I think I finally understand the point you're making, so let me ask the obvious question. If we were able to revert to section 21.02 but use the definition that I have provided in amendment Lib-1 insofar as “pharmaceutical product” is concerned, would we achieve the intention that I was hoping to achieve?
On October 28th, 2010. See this statement in context.